Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2022-09-09
2023-05-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease
NCT02012647
Deep Brain Stimulation for Parkinson's Disease: the Globus Pallidus Internus Versus Subthalamic Nucleus
NCT02647372
Combined Deep Brain Stimulation for Parkinson's Disease
NCT01485276
Sub-thalamic Nucleus Stimulation in Parkinson Disease
NCT01817088
Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait
NCT06994728
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to evaluate the effect of combined (C) stimulation of the STN and SNr on FoG if compared to standard (S) stimulation of the STN at 130 Hz, over one month. Based on previous literature evidence as primary aim the respective effect of two setting of C-stimulation will be separately assessed: a) C1- stimulation, with HF stimulation of the STN and SNr using a 'interleaved pulses' at 125 Hz vs. S- stimulation, over one month; b) C2-stimulation with LF stimulation of the SNr at 60Hz and HF stimulation of the STN vs. S- stimulation, over one month.
Other objectives are to evaluate the:
* Tolerance of combined stimulation (STN + SNr) through the collection of adverse events (AEs)
* Development of psychic events such as the presence of depression or dysphoria
* Effect of C (C1 and C2) -stimulation on walking disorders and other axial symptoms if compared vs. the S-stimulation.
* Effect of C (C1 and C2) -stimulation on PD's motor symptoms and motor complications if compared vs. the S-stimulation.
* Effect of C (C1 and C2) -stimulation on sleep quality if compared vs. the S-stimulation.
Each patient will have the 3 types of stimulation:
1. One month of S-stimulation (130hz, STN).
2. One month of C1- stimulation;
3. One month of C2- stimulation;
Stimulation setting order will be randomly assigned. Minimal dopaminergic treatment adjustment will be allowed to minimize the drop-out rate (± 100 mg of levodopa equivalent daily dose) and registered
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
the sequence of different stimulation parameters will be randomized and not the treatment Each patient receives the three treatments (S, C1 and C2)
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
S Stimulation
Standard STN DBS defined as high frequency at 130Hz stimulation
1 : S-C1-C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
2 : S-C2-C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
3 : C1 - S - C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
4 : C1 -C2 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
5 : C2 - S - C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
6 : C2 - C1 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
C1 Stimulation
Combined high frequency stimulation of the STN and SNr using an interleaved pulses at 125Hz
1 : S-C1-C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
2 : S-C2-C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
3 : C1 - S - C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
4 : C1 -C2 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
5 : C2 - S - C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
6 : C2 - C1 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
C2 Stimulation
Combined low frequency stimulation of the SNr at 60Hz and high frequency stimulation of the STN
1 : S-C1-C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
2 : S-C2-C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
3 : C1 - S - C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
4 : C1 -C2 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
5 : C2 - S - C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
6 : C2 - C1 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1 : S-C1-C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
2 : S-C2-C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
3 : C1 - S - C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
4 : C1 -C2 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
5 : C2 - S - C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
6 : C2 - C1 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :
* Standard stimulation
* 125Hz at both STN and SNr for C1,
* 125Hz for STN and 60 for SNr for C2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients submitted to STN-DBS, for at least 6 months;
3. Patients with STN-DBS at 130Hz;
4. Patients with a troublesome FoG according to the "NFOG-Q", Part II Item II ≥ 2 or Part III Item 7 ≥ 2;
5. Mini Mental State (MMS) ≥ 25 ;
6. Ventral contact of electrodes implanted in the SNr (according to analysis of activated tissue volume models (VTA));
7. Patients with stable parkinsonian stimulation parameters and anti-parkinsonian treatments for one month before the inclusion visit;
8. Patients with H/Y stage ≤ 3 in the Med ON/Stim On condition (at 130Hz, S-stimulation);
Exclusion Criteria
2. Patient with severe FoG before DBS, i.e. MDS-UPDRS item 2.13 in Med ON ≥2 or MDS-UPDRS item 3.11 ≥2 in Med On;
3. Patient whose antiparkinsonian treatments were modified during the last month before inclusion;
4. Patient with H\&Y stage ≥4 in Med On/Stim On (at 130Hz, S-stimulation) ;
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Margherita FABBRI, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uh Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Artusi CA, Ledda C, Gallo S, Rinaldi D, Campisi C, Rousseau V, Thalamas C, Barbosa R, Ory-Magne F, Brefel-Courbon C, Rascol O, de Barros A, Harroch E, Zibetti M, Rizzone MG, Romagnolo A, Imbalzano G, Lopiano L, Houeto JL, Fabbri M. Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial. J Parkinsons Dis. 2024 Nov;14(8):1602-1613. doi: 10.1177/1877718X241292315. Epub 2025 Jan 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC31/21/0609
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.